The protective and pathologic features of the LASV immune response (LASV legacy) - modified project summary/abstract section lassa virus (LASV) is a persistent global public health threat that infects…
Active Grant Awarded Last action
- Award ID
- R01AI190076
- Recipient
-
University Of North Carolina At Chapel Hill UEI D3LHU66KBLD5 Part of University Of North Carolina System Office
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $675,339
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 11% complete
- Place of performance
- Chapel Hill, NC 27599, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded University of North Carolina at Chapel Hill a $675,339 grant on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, R01AI190076, runs through April 30, 2031, with place of performance in Chapel Hill, NC 27599, USA.
The funded work is the LASV Legacy study of the protective and pathologic features of the Lassa virus immune response. Its aims are to characterize and compare humoral and cellular immune responses following subclinical Lassa virus (LASV) infection and Lassa fever (LF), to describe the prevalence, characteristics, and natural history of long-term clinical complications of LASV infection and LF, and to explore their association with host, viral, and immune response factors.
Two sub-awards deliver specific work. La Jolla Institute for Immunology (award dated September 8, 2026) will test serum samples for humoral immune response from 75 LASV infection survivors, 75 severe LF survivors, and 75 seronegative controls at four time points; test peripheral blood mononuclear cells (PBMCs) for cellular immune response using AIMS/ICS/FCS; and share the humoral and cellular assay data for analysis. Phebe Hospital (award dated August 27, 2026) will assist with establishing an LF survivor cohort, continue providing care to patients with acute LF, and collaborate with UNC on collecting clinical data and biospecimens from patients with acute LF.
Description
The protective and pathologic features of the LASV immune response (LASV legacy) - modified project summary/abstract section lassa virus (LASV) is a persistent global public health threat that infects 2.7M and kills more than 5,000 individuals each year, principally in nigeria, liberia, and sierra leone. Annual outbreaks of lassa fever (LF) contribute to more infections and deaths than all outbreaks of filoviruses, including ebola virus, combined and is the most common cause of imported viral hemorrhagic fever to non-endemic countries. The permanence of LASV in the rodent reservoir in west africa, coupled an expansion of their range and numbers have led to a steady increase in LF in this region. Despite the burden of LASV infection in west africa there remain substantial gaps in our understanding of fundamental aspects of this emerging infection including host humoral and cellular immune responses to LASV, their potential protective and pathologic roles in LASV-related disease, and longterm complications of LF. The overarching objective of the proposed studies is to rigorously characterize the longitudinal humoral and cellular response to LASV across the spectrum of illness severity, identify the longerterm consequences of both LASV infection and LF, and evaluate the role of sustained immune activation as a pathogenic mechanism underlying LF and LASV infection sequelae. Specifically: aim I: characterize and compare the humoral and cellular immune responses following subclinical LASV infection and LF. Aim 2: describe the prevalence, characteristics, and natural history of long-term clinical complications of LASV infection and LF and explore their association with host, viral and immune response factors. The findings of these investigations will have direct and practical value for the design of trials of LASV vaccine candidates and potentially identify strategies to prevent and treat longer-term sequelae of LASV infection. We will conduct this work in the context of close and strong working relationships with healthcare and community leaders in a hyperendemic region for lassa fever and well-developed infrastructure for clinical research that we have established in liberia where we have recruited, enrolled, and longitudinally followed and sampled more than 5000 participants including 79 patients with acute LF, 68 with subclinical LASV infection and 61 survivors of severe LF as well as hundreds of uninfected seronegative controls. The proposed work will provide a muchneeded longitudinal characterization of the humoral and cellular immune responses, evaluation of the long-term complications of subclinical LASV infection/severe LF and investigation of sustained immune activation as a mechanism underlying the long-term complications of surviving subclinical LASV infection/severe LF. With yearly outbreaks, this study will ensure that the world is better prepared through an improved understanding of the durability of the humoral and cellular immune responses to infection and of the clinical complications of LASV infection across the spectrum of disease severity.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $42,120 | |
| Original award | $633,219 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| La Jolla Institute For Immunology | $135,925 | |
| Phebe Hospital | $42,120 |
Quick answers
Who received award R01AI190076?
R01AI190076 was awarded to University Of North Carolina At Chapel Hill by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 1, 2026.
How much is award R01AI190076 worth?
$675,339 has been obligated on R01AI190076.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award